Developer docs
API playgroundTry for free, no card

Search company profiles

AnaptysBio

Full company profile

uuid00024cx

Namestring
AnaptysBio
Legal namestring
AnaptysBio, Inc.
Websiteurl
anaptysbio.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

AnaptysBio, Inc. (NASDAQ: ANAB) is a publicly traded, virtual royalty management company headquartered in San Diego, California. Effective April 20, 2026, the company spun off its biopharma development operations into First Tracks Biotherapeutics (NASDAQ: TRAX) and now operates with fewer than 10 FTEs and less than $10M in annualized operating expenses, targeting greater than 95% EBIT margins.

AnaptysBio's sole business is managing two contracted royalty streams from out-licensed pharmaceutical assets: (1) tiered royalties of 8-25% on worldwide net sales of Jemperli (dostarlimab), a PD-1 antagonist originally discovered by AnaptysBio and now commercialized by GSK for endometrial cancer and dMMR pan tumors, with ongoing label-expansion studies in rectal, colon, and head and neck cancers; and (2) a 10% royalty on global net sales of imsidolimab, an IL-36R antagonist for generalized pustular psoriasis, licensed exclusively to Vanda Pharmaceuticals with an FDA BLA target action date of December 12, 2026. The company previously monetized $300M of Jemperli receivables through a non-recourse facility with Sagard Healthcare Royalty Partners, with cumulative $600M payable to Sagard by March 31, 2031.

The company's revenue mechanics are driven entirely by partner commercialization performance rather than by AnaptysBio's own sales activity. Capital allocation is oriented toward share repurchases ($100M authorized) and future royalty acquisitions, supported by approximately $140-145M in net cash post-spin-off. Jemperli Q1 2026 sales of $313M (more than 40% YoY growth) and FY 2025 sales of $1.128B (89% YoY growth) underpin a projected annualized royalty run-rate exceeding $390M as early as 2029, contingent on GSK reaching its guided $2.7B+ peak monotherapy sales target. The April 2026 Delaware Chancery Court ruling dismissed Tesaro's challenge to the royalty structure, contractually preserving the 8-25% tiered rates through patent expiry in 2035-2038.

Short descriptiontext

AnaptysBio is a virtual, publicly traded royalty management company managing contracted royalty streams on Jemperli (GSK, tiered 8-25%) and imsidolimab (Vanda, 10%) following its April 2026 spin-off of biopharma operations into First Tracks Biotherapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical royalties, biotech licensing, antibody therapeutics, drug royalty management, financial collaborations
Industry1 code
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Royalty Management
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Jemperli Royalties (GSK)
TypeLicensing Royalties
Description

Tiered royalty structure on annual worldwide net sales: 8% on sales up to $1B, 12% on $1.0-1.5B, 20% on $1.5-2.5B, 25% on sales exceeding $2.5B. Royalty rates preserved through 2035 (US) and 2036 (EU) following court ruling dismissing Tesaro's breach claim. Following capped non-recourse monetizations of $300MM, receivables payable to Sagard Healthcare Royalty Partners until cumulative $600MM paydown by March 31, 2031.

anaptysbio.com
2Imsidolimab Royalties (Vanda)
TypeLicensing Royalties
Description

10% royalties on global net sales of imsidolimab for generalized pustular psoriasis. Vanda holds exclusive global license. FDA BLA accepted with target action date of December 12, 2026. Regulatory and patent exclusivity expected to extend into late 2030s.

anaptysbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Others, Technology or R&D
Pricing details1 tier
1Jemperli tiered royalties: 8% ($0-$1B), 12% ($1-1.5B), 20% ($1.5-2.5B), 25% (>$2.5B)
ModelOtherBilling cadenceOther
Notes

Royalty rates apply to annual worldwide net sales of Jemperli. Composition of matter patent expires 2035 (US), 2036 (EU), 2037 (Japan), with potential extensions to 2038.

anaptysbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Jemperli
Description

PD-1 antagonist drug (dostarlimab) approved for endometrial cancer and dMMR pan tumors, partnered with GSK. Anaptys receives tiered royalties of 8%-25% on net sales.

anaptysbio.com
+1 more record
Core offering1 text field

AnaptysBio is a virtual pharmaceutical royalty management company that manages two financial collaborations: tiered royalties of 8%-25% on worldwide net sales of Jemperli (dostarlimab), a PD-1 antagonist approved for endometrial cancer and dMMR pan tumors and commercialized by GSK; and 10% royalties on global net sales of imsidolimab, an IL-36 receptor antagonist licensed to Vanda Pharmaceuticals for generalized pustular psoriasis. Following the April 2026 spin-off of its biopharma operations into First Tracks Biotherapeutics, the company operates with fewer than 10 FTEs and focuses exclusively on protecting and maximizing these royalty streams.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Jemperli sales growing >40% YoY with Q1 2026 sales of $313MM and FY 2025 sales of $1.128B
+3 more records
Product overview1 text field

AnaptysBio operates as a virtual royalty management company with a lean operating model (less than 10 FTEs, less than $10 million annualized operating expenses, greater than 95% EBIT margin). The company exclusively manages two financial collaborations: (1) Jemperli (dostarlimab) with GSK, a PD-1 antagonist approved for endometrial cancer and dMMR pan tumors, generating tiered royalties of 8%-25% on annual worldwide net sales based on sales tiers ($0-1B at 8%, $1-1.5B at 12%, $1.5-2.5B at 20%, and >$2.5B at 25%); and (2) imsidolimab with Vanda, an IL-36R antagonist for generalized pustular psoriasis (GPP), generating 10% royalties on global net sales. The company spun off its biopharma development operations into First Tracks Biotherapeutics in April 2026 to focus solely on royalty stream management.

Product and service1 record
1Jemperli (dostarlimab) Royalty Management
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierSupportingTypeOthersAnnounced on2026-05-11
Description

CEO of XOMA Royalty, added to Board of Directors to strengthen leadership with expertise in royalty management and biotech finance.

Strategic tierSupportingTypeOthersAnnounced on2026-05-11
Description

Appointed CFO in May 2026, bringing extensive experience in finance, business development, and royalty management from prior roles at Third Harmonic Bio and Horizon Therapeutics.

3Vanda Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Exclusive global license to Vanda for imsidolimab, an IL-36R antagonist for generalized pustular psoriasis (GPP). Vanda submitted BLA to FDA (accepted, target action date December 12, 2026). Anaptys receives 10% royalties on global net sales. Regulatory and patent exclusivity expected into late 2030s.

anaptysbio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Financial collaboration focused on development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist approved for endometrial cancer and dMMR pan tumors, with ongoing studies in rectal cancer, colon cancer, and head and neck squamous cell carcinoma. Tiered royalty structure of 8-25% on annual worldwide net sales. GSK guiding to >$2.7 billion peak monotherapy sales for Jemperli.

Strategic tierSupportingTypeOthers
Description

Former CFO of Royalty Pharma, appointed to Board of Directors to leverage corporate and royalty finance expertise following the company's transition to a pure-play royalty management model.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

OrbiMed is a healthcare-dedicated investment firm with a growing royalty and structured financing practice alongside its private equity and public equity strategies. Comparable to AnaptysBio as a source of competing royalty capital and as a potential acquirer/investor in pharma royalty streams.

TypeDirect peer
Description

Royalty Pharma (NASDAQ: RPRX) is the largest pharmaceutical royalty acquisition company, purchasing royalty interests in marketed and late-stage therapies. It is the most directly comparable peer to AnaptysBio's pure-play royalty model, with a similar emphasis on tiered/long-duration royalties and capital return to shareholders. Susannah Gray, AnaptysBio board member, was previously EVP Finance and CFO of Royalty Pharma.

TypeDirect peer
Description

HealthCare Royalty Partners (HCR) is a private investment firm that provides capital to healthcare companies through structured royalties and debt instruments. It is a direct peer to AnaptysBio's royalty management focus, with similar late-stage therapeutic royalty portfolios and is one of the established non-bank royalty capital providers in the market.

TypeEmerging player
Description

Innovatus Capital Partners operates a life sciences royalty and structured financing strategy focused on commercial-stage and near-commercial healthcare assets. Comparable to AnaptysBio's royalty management approach with similar asset types and counterparty profiles (pharma/biotech licensors).

TypeDirect peer
Description

XOMA Royalty (NASDAQ: XOMA) acquires and manages royalty and milestone interests in pre-commercial and commercial therapeutic assets, primarily in biotech. It is a direct peer to AnaptysBio's royalty management model with similar lean operating economics and a focus on late-stage assets. Owen Hughes, AnaptysBio board member, is CEO of XOMA Royalty.

TypeDirect peer
Description

DRI Healthcare Trust (TSX: DHT.UN) acquires, manages and grows royalty interests in healthcare products, with a portfolio concentrated in approved and commercial-stage therapies. It is a directly comparable royalty acquirer/manager to AnaptysBio's pure-play model, with overlapping assets in inflammation and immunology therapeutic areas.

TypeEmerging player
Description

Compass Therapeutics (NASDAQ: CMPX) is a clinical-stage oncology company developing antibody-based immunotherapies. Partially comparable to AnaptysBio's pre-spin-off discovery capabilities and to its current antibody royalty asset (Jemperli) given overlapping immuno-oncology therapeutic area.

TypeEmerging player
Description

Zymeworks (NASDAQ: ZYME) is a clinical-stage biotechnology company developing multifunctional biotherapeutics, with multiple pharma licensing partnerships. Comparable to AnaptysBio's original out-licensing model for antibodies and to board member connections (Oleg Nodelman and Hollings Renton both serve on Zymeworks' board).

TypeEmerging player
Description

MacroGenics (NASDAQ: MGNX) is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer and autoimmune disease, overlapping with AnaptysBio's historical immuno-oncology (PD-1) and immunology (IL-36R) discovery focus. Comparable as a biologics platform peer rather than as a royalty comp.

TypeBroad incumbent
Description

Regeneron (NASDAQ: REGN) is a large established biopharmaceutical company commercializing multiple therapeutic antibodies including immuno-oncology assets. While broader and vertically integrated, it is comparable as a leading antibody therapeutics platform and a potential acquirer of or competitor to AnaptysBio's PD-1/IL-36R antibody programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AnaptysBio

Biopharmaceutical Royalty Managementanaptysbio.com

AnaptysBio is a virtual, publicly traded royalty management company managing contracted royalty streams on Jemperli (GSK, tiered 8-25%) and imsidolimab (Vanda, 10%) following its April 2026 spin-off of biopharma operations into First Tracks Biotherapeutics.

What AnaptysBio does

AnaptysBio, Inc. (NASDAQ: ANAB) is a publicly traded, virtual royalty management company headquartered in San Diego, California. Effective April 20, 2026, the company spun off its biopharma development operations into First Tracks Biotherapeutics (NASDAQ: TRAX) and now operates with fewer than 10 FTEs and less than $10M in annualized operating expenses, targeting greater than 95% EBIT margins.

AnaptysBio's sole business is managing two contracted royalty streams from out-licensed pharmaceutical assets: (1) tiered royalties of 8-25% on worldwide net sales of Jemperli (dostarlimab), a PD-1 antagonist originally discovered by AnaptysBio and now commercialized by GSK for endometrial cancer and dMMR pan tumors, with ongoing label-expansion studies in rectal, colon, and head and neck cancers; and (2) a 10% royalty on global net sales of imsidolimab, an IL-36R antagonist for generalized pustular psoriasis, licensed exclusively to Vanda Pharmaceuticals with an FDA BLA target action date of December 12, 2026. The company previously monetized $300M of Jemperli receivables through a non-recourse facility with Sagard Healthcare Royalty Partners, with cumulative $600M payable to Sagard by March 31, 2031.

The company's revenue mechanics are driven entirely by partner commercialization performance rather than by AnaptysBio's own sales activity. Capital allocation is oriented toward share repurchases ($100M authorized) and future royalty acquisitions, supported by approximately $140-145M in net cash post-spin-off. Jemperli Q1 2026 sales of $313M (more than 40% YoY growth) and FY 2025 sales of $1.128B (89% YoY growth) underpin a projected annualized royalty run-rate exceeding $390M as early as 2029, contingent on GSK reaching its guided $2.7B+ peak monotherapy sales target. The April 2026 Delaware Chancery Court ruling dismissed Tesaro's challenge to the royalty structure, contractually preserving the 8-25% tiered rates through patent expiry in 2035-2038.

AnaptysBio firmographics

Firmographics
Name
AnaptysBio
Legal name
AnaptysBio, Inc.
Website
https://anaptysbio.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
AnaptysBio is a virtual, publicly traded royalty management company managing contracted royalty streams on Jemperli (GSK, tiered 8-25%) and imsidolimab (Vanda, 10%) following its April 2026 spin-off of biopharma operations into First Tracks Biotherapeutics.
Ownership category
akta.pro rank

AnaptysBio industry classification

Industry
Product category
Biopharmaceutical Royalty Management
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Pharmaceutical royalties
  • Biotech licensing
  • Antibody therapeutics
  • Drug royalty management
  • Financial collaborations

Where AnaptysBio is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AnaptysBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others, Technology or R&D

Revenue model

  1. Jemperli Royalties (GSK): Tiered royalty structure on annual worldwide net sales: 8% on sales up to $1B, 12% on $1.0-1.5B, 20% on $1.5-2.5B, 25% on sales exceeding $2.5B. Royalty rates preserved through 2035 (US) and 2036 (EU) following court ruling dismissing Tesaro's breach claim. Following capped non-recourse monetizations of $300MM, receivables payable to Sagard Healthcare Royalty Partners until cumulative $600MM paydown by March 31, 2031.
  2. Imsidolimab Royalties (Vanda): 10% royalties on global net sales of imsidolimab for generalized pustular psoriasis. Vanda holds exclusive global license. FDA BLA accepted with target action date of December 12, 2026. Regulatory and patent exclusivity expected to extend into late 2030s.

Pricing tiers

ModelBillingPrice
OtherOtherJemperli tiered royalties: 8% ($0-$1B), 12% ($1-1.5B), 20% ($1.5-2.5B), 25% (>$2.5B)

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

AnaptysBio product offering

Product offering

Core offering

AnaptysBio is a virtual pharmaceutical royalty management company that manages two financial collaborations: tiered royalties of 8%-25% on worldwide net sales of Jemperli (dostarlimab), a PD-1 antagonist approved for endometrial cancer and dMMR pan tumors and commercialized by GSK; and 10% royalties on global net sales of imsidolimab, an IL-36 receptor antagonist licensed to Vanda Pharmaceuticals for generalized pustular psoriasis. Following the April 2026 spin-off of its biopharma operations into First Tracks Biotherapeutics, the company operates with fewer than 10 FTEs and focuses exclusively on protecting and maximizing these royalty streams.

Product overview

AnaptysBio operates as a virtual royalty management company with a lean operating model (less than 10 FTEs, less than $10 million annualized operating expenses, greater than 95% EBIT margin). The company exclusively manages two financial collaborations: (1) Jemperli (dostarlimab) with GSK, a PD-1 antagonist approved for endometrial cancer and dMMR pan tumors, generating tiered royalties of 8%-25% on annual worldwide net sales based on sales tiers ($0-1B at 8%, $1-1.5B at 12%, $1.5-2.5B at 20%, and >$2.5B at 25%); and (2) imsidolimab with Vanda, an IL-36R antagonist for generalized pustular psoriasis (GPP), generating 10% royalties on global net sales. The company spun off its biopharma development operations into First Tracks Biotherapeutics in April 2026 to focus solely on royalty stream management.

Differentiator

Problem solved

Functional benefit

Brands

  • Jemperli: PD-1 antagonist drug (dostarlimab) approved for endometrial cancer and dMMR pan tumors, partnered with GSK. Anaptys receives tiered royalties of 8%-25% on net sales.
  • imsidolimab

Products and services

  • Jemperli (dostarlimab) Royalty Management

Quantifiable outcome

  • Jemperli sales growing >40% YoY with Q1 2026 sales of $313MM and FY 2025 sales of $1.128B
  • +3 more outcomes

Companies that use AnaptysBio

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles2 records

AnaptysBio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

AnaptysBio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered supporting and core.

  • Owen HughessupportingOthers · 11 May 2026CEO of XOMA Royalty, added to Board of Directors to strengthen leadership with expertise in royalty management and biotech finance.
  • Christopher MurphysupportingOthers · 11 May 2026Appointed CFO in May 2026, bringing extensive experience in finance, business development, and royalty management from prior roles at Third Harmonic Bio and Horizon Therapeutics.
  • Vanda PharmaceuticalscoreStrategic or Co-development Partner · 1 February 2025Exclusive global license to Vanda for imsidolimab, an IL-36R antagonist for generalized pustular psoriasis (GPP). Vanda submitted BLA to FDA (accepted, target action date December 12, 2026). Anaptys receives 10% royalties on global net sales. Regulatory and patent exclusivity expected into late 2030s.
  • GSK (GlaxoSmithKline)coreStrategic or Co-development PartnerFinancial collaboration focused on development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist approved for endometrial cancer and dMMR pan tumors, with ongoing studies in rectal cancer, colon cancer, and head and neck squamous cell carcinoma. Tiered royalty structure of 8-25% on annual worldwide net sales. GSK guiding to >$2.7 billion peak monotherapy sales for Jemperli.
  • Susannah GraysupportingOthersFormer CFO of Royalty Pharma, appointed to Board of Directors to leverage corporate and royalty finance expertise following the company's transition to a pure-play royalty management model.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

AnaptysBio competitors and assessment

Company assessment

Emerging players

  • OrbiMed Advisors: OrbiMed is a healthcare-dedicated investment firm with a growing royalty and structured financing practice alongside its private equity and public equity strategies. Comparable to AnaptysBio as a source of competing royalty capital and as a potential acquirer/investor in pharma royalty streams.
  • Innovatus Capital Partners: Innovatus Capital Partners operates a life sciences royalty and structured financing strategy focused on commercial-stage and near-commercial healthcare assets. Comparable to AnaptysBio's royalty management approach with similar asset types and counterparty profiles (pharma/biotech licensors).
  • Compass Therapeutics: Compass Therapeutics (NASDAQ: CMPX) is a clinical-stage oncology company developing antibody-based immunotherapies. Partially comparable to AnaptysBio's pre-spin-off discovery capabilities and to its current antibody royalty asset (Jemperli) given overlapping immuno-oncology therapeutic area.
  • Zymeworks: Zymeworks (NASDAQ: ZYME) is a clinical-stage biotechnology company developing multifunctional biotherapeutics, with multiple pharma licensing partnerships. Comparable to AnaptysBio's original out-licensing model for antibodies and to board member connections (Oleg Nodelman and Hollings Renton both serve on Zymeworks' board).
  • MacroGenics: MacroGenics (NASDAQ: MGNX) is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer and autoimmune disease, overlapping with AnaptysBio's historical immuno-oncology (PD-1) and immunology (IL-36R) discovery focus. Comparable as a biologics platform peer rather than as a royalty comp.

Direct peers

  • Royalty Pharma: Royalty Pharma (NASDAQ: RPRX) is the largest pharmaceutical royalty acquisition company, purchasing royalty interests in marketed and late-stage therapies. It is the most directly comparable peer to AnaptysBio's pure-play royalty model, with a similar emphasis on tiered/long-duration royalties and capital return to shareholders. Susannah Gray, AnaptysBio board member, was previously EVP Finance and CFO of Royalty Pharma.
  • HealthCare Royalty Partners: HealthCare Royalty Partners (HCR) is a private investment firm that provides capital to healthcare companies through structured royalties and debt instruments. It is a direct peer to AnaptysBio's royalty management focus, with similar late-stage therapeutic royalty portfolios and is one of the established non-bank royalty capital providers in the market.
  • XOMA Royalty: XOMA Royalty (NASDAQ: XOMA) acquires and manages royalty and milestone interests in pre-commercial and commercial therapeutic assets, primarily in biotech. It is a direct peer to AnaptysBio's royalty management model with similar lean operating economics and a focus on late-stage assets. Owen Hughes, AnaptysBio board member, is CEO of XOMA Royalty.
  • DRI Healthcare Trust: DRI Healthcare Trust (TSX: DHT.UN) acquires, manages and grows royalty interests in healthcare products, with a portfolio concentrated in approved and commercial-stage therapies. It is a directly comparable royalty acquirer/manager to AnaptysBio's pure-play model, with overlapping assets in inflammation and immunology therapeutic areas.

Broad incumbents

  • Regeneron Pharmaceuticals: Regeneron (NASDAQ: REGN) is a large established biopharmaceutical company commercializing multiple therapeutic antibodies including immuno-oncology assets. While broader and vertically integrated, it is comparable as a leading antibody therapeutics platform and a potential acquirer of or competitor to AnaptysBio's PD-1/IL-36R antibody programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

AnaptysBio social profiles

Digital presence

AnaptysBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AnaptysBio leadership team

Management profile

Number of profiles

Profiles8 records

AnaptysBio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AnaptysBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AnaptysBio

What does AnaptysBio do?

AnaptysBio is a virtual pharmaceutical royalty management company that manages two financial collaborations: tiered royalties of 8%-25% on worldwide net sales of Jemperli (dostarlimab), a PD-1 antagonist approved for endometrial cancer and dMMR pan tumors and commercialized by GSK; and 10% royalties on global net sales of imsidolimab, an IL-36 receptor antagonist licensed to Vanda Pharmaceuticals for generalized pustular psoriasis. Following the April 2026 spin-off of its biopharma operations into First Tracks Biotherapeutics, the company operates with fewer than 10 FTEs and focuses exclusively on protecting and maximizing these royalty streams.

Is AnaptysBio a public or private company?

AnaptysBio is a public company. It is classified as public and is currently operating.

When was AnaptysBio founded?

AnaptysBio was founded in 2005. It employs 51 to 100 people.

Where is AnaptysBio based?

AnaptysBio is headquartered in San Diego, United States, in the North America region.

How does AnaptysBio make money?

Two revenue lines are on record. Jemperli Royalties (GSK) is the primary driver. The others are imsidolimab Royalties (Vanda).

Who are AnaptysBio's main competitors?

Emerging players on record are OrbiMed Advisors, Innovatus Capital Partners, Compass Therapeutics, Zymeworks and MacroGenics. Direct peers are Royalty Pharma, HealthCare Royalty Partners, XOMA Royalty and DRI Healthcare Trust. Regeneron Pharmaceuticals is listed as a broad incumbent.

Does AnaptysBio have an API?

No public API is recorded for AnaptysBio.

What industry is AnaptysBio in?

AnaptysBio's product category is Biopharmaceutical Royalty Management. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingEcoR1 Capital Reports Acquisition of $17.22 Million in AnaptysBio Common SharesAnaptysBio director Oleg Nodelman and EcoR1 Capital purchased 374,580 common shares, increasing their indirect beneficial ownership to 8,254,674 shares. The transactions were reported on November 18, 2026, via EDGAR.Seeking AlphaAnaptysBio, Inc. (ANAB) Presents at UBS Global Biopharma Conference 2026 TranscriptAnaptysBio completed its spin-off of biopharma operations on April 20th, transforming into a virtual organization with no employees. The company now operates on two royalty threads: Jemperli, a PD-1 antagonist sold by GSK, and another product.Investing.comAnaptysBio at UBS Global Biopharma Conference 2026: Royalty growth, legal riskAnaptysBio outlined its virtual, royalty-focused business at the UBS Global Biopharma Conference, citing Jemperli's $1 billion cumulative revenue and 30% annual growth. The company warned that a GSK lawsuit could determine whether Jemperli reverts to AnaptysBio, with a court decision expected in late 2024 or early 2025.The future of tradingAnaptysBio Announces Participation in Three Investor ConferencesAnaptysBio executives will participate in fireside chats at three investor conferences: CEO Daniel Faga at UBS Global Biopharma in London on Nov. 17, 2026, and CFO Chris Murphy at Piper Sandler and Evercore conferences in New York and Miami on Dec. 2, 2026. The company also includes one-on-one investor meetings at the Piper Sandler event.Stock TitanAnaptysBio to Join Three Investor ConferencesAnaptysBio announced its executives will attend three investor conferences in London, New York, and Miami. CEO Daniel Faga and CFO Chris Murphy will participate in fireside chats and meetings on November 17 and December 2, 2026. Live webcasts will be available on the company's investor website.MarketBeat50,762 AnaptysBio, Inc. $ANAB Shares Bought by Moody Aldrich Partners LLCMoody Aldrich Partners LLC raised its AnaptysBio stake by 164.1% in Q3, buying 50,762 shares to own 81,688 shares (0.27% of the company). Other funds also adjusted positions, and analysts rate the stock a Moderate Buy with a $77.79 average price target.Seeking AlphaDiamond Hill Small-Mid Cap Fund Q3 2026 CommentarySmall- and mid-cap US equities declined in Q3 2026, trailing larger-cap stocks after a Fed rate hike and rising Treasury yields. Health care led gains, while consumer-sensitive areas underperformed; the fund reduced consumer exposure and added positions in Transocean and AnaptysBio.Business & FinancialAlopecia Areata Pipeline 2026: Inside The Clinical Trial Landscape, Therapeutic Assessment, And Key Companies Involved Pfizer, Legacy Healthcare, Anaptysbio, Eli Lilly And Company, Incyte, NovartisDelveInsight's 2026 Alopecia Areata pipeline report covers 18+ companies developing 20+ therapies. The FDA approved Olumiant for adolescents in September 2026, and Nektar's REZPEG showed 75% sustained response in Phase IIb. Upadacitinib Phase III trials met endpoints in August 2026.